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Abstract
Chronic autoimmune thyroiditis or Hashimoto’s thyroiditis (HT) is the most common cause of thyroid
diseases in children and adolescents. It is also the most common cause of acquired hypothyroidism with
or without goiter. The incidence of autoimmune thyroiditis has increased dramatically over the past few
decades, affecting up to 5% of the general population in iodine sufficient areas. HT is caused by the
complex interplay of genetic, environmental, and endogenous factors. Significant progress has been
made in identifying and characterizing the genes involved in pathogenesis of the disease.
The aim of this  review is to analyze current opinions and options regarding the etiology, genetic
contribution to the pathogenesis, evaluation, diagnosis, treatment, and prognosis of the HT in children.
Introduction
Chronic autoimmune thyroiditis (chronic
lymphocytic thyroiditis or Hashimoto’s thyroiditis) is the
most common endocrine disorder in childhood and
adolescence. Also it is the most common cause of
acquired hypothyroidism in children. Thyroid hormones
have critical impact on early brain development, somatic
growth, bone maturation; they play a role in synthesis of
more than 100 proteins that constantly regulate each
and every function in the body. Optimal thyroid hormone
quantity is important because a prolonged hypothyroid
state before starting treatment in children may result in
incomplete catch-up growth [1], obesity [2] and precocious
pseudo-puberty [3].
Hashimoto thyroiditis (HT) results from complex
cellular and humoral immune reactions to thyroid antigens
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that occur in genetically predisposed individuals
presumably triggered by some environmental factor.
Advances in molecular methods in the past
years enabled significant progress in our understanding
of the immunogenetic mechanisms leading to thyroid
autoimmunity. Genetic analyses undertaken in the last
decade have revealed a completely new picture of
autoimmune thyroid disease pathogenesis and raised
awareness of heterogeneity among individuals and
populations.
This review will summarize the current studies
regarding the etiology, genetic susceptibility,
pathogenesis, evaluation, diagnosis, treatment and
prognosis of Hashimoto thyroiditis in children.
Methods
Electronic bases: PubMed, Medline, Cochrane
Database of Systematic Reviews were searched for
relevant articles using the key words: autoimmune
thyroiditis, Hashimoto thyroiditis, chronic lymphocitytic
thyroiditis, children, goiter, and hypothyroidism. The
main papers analyzed were original studies, review
articles and clinical practice guidelines. Reference lists
of the relevant articles were scanned for additional
studies.
Studies were selected according to the following
criteria: 1) original studies reporting the epidemiological
and clinical characteristics of the disease, 2) original
data reporting clinical course and long term outcome; 3)
recent review articles analyzing the genes involved in
the thyroid autoimmunity.
Studies published in English and in other
languages were included.
Textbooks of pediatrics and pediatric
endocrinology available in print or online version that




Autoimmune thyroiditis or chronic lymphocytic
thyroiditis is defined as evidence of “intrathyroidal
lymphocytic infiltration” with or without follicular damage.
Two types of autoimmune thyroiditis are causes
of persistent hypothyroidism: Hashimoto’s disease
(goitrous form) and atrophic thyroiditis (nongoitrous form).
Both are characterized by circulating thyroid
autoantibodies and varying degrees of thyroid
dysfunction, the only difference being the presence or
absence of goiter.
In 1912, Hashimoto first described chronic
lymphocytic thyroiditis in women with asymptomatic
goiter. After surgical removal of the gland, the author
classified it as struma lymphomatosa, apparent
transformation of thyroid into lymphoid tissue.
Later on, in 1938, diagnosis was made in children
presenting goiter with lymphocytic infiltrate. Until 1956,
when antibodies were detected, it was considered a rare
disease in pediatrics, but since then incidence is rapidly
increasing.
Epidemiology
Autoimmune thyroid disease (ATD) is the most
common organ-specific autoimmune condition, affecting
up to 5% of the general population [4]. Although the
prevalence peaks in adulthood; it is also the most
common etiology of acquired thyroid disease in children
and adolescents in iodine sufficient areas.
The frequency of HT has been reported to be
between 0.3 % and 9.6 % in children and adolescent age
groups [5, 6].
The prevalence reported in the studies varies
mainly depending on the diagnostic criteria, ethnicity,
iodine status and age or sex of the population studied.
Autoimmune thyroiditis is being increasingly
identified in the young population due to various reasons,
such as increasing awareness, availability of better
antibody assays, and skilled cytopathologists to perform
and interpret fine needle aspirations. In recent years
several studies assessing clinical and epidemiological
characteristics of children and adolescents with HT have
been published in the literature (Table 1) [7-12].
The childhood prevalence peaks in early to mid-
puberty, and in all of the studies female predominance is
reported up to 10-15:1. Presentation is rare under the
age of 3 years, but cases have been reported even in
infancy [13].
An increased frequency of ATDs is reported in
Turner syndrome and in other nondisjunctional





The theory that maternal autoimmunity may lead to the
preferential survival of a fetus with chromosomal
aneuploidy remains unproven [14]. The most prevalent
autoimmune disorder in Turner syndrome appears to be
chronic autoimmune thyroiditis, with a reported thyroid
autoantibody incidence in 30– 50% of patients.
Hypothyroidism of autoimmune origin is so common in
Turner syndrome that almost every second Turner
syndrome woman will probably develop hypothyroidism,
and it will increase with age [15, 16].
Clinically similar and antibodies negative
hypothyroidism frequently described in obese children
should be distinguished from HT, although classical HT
might appear in this population [17].
Etiology
Autoimmune thyroid disorders result from a
complex interplay of genetic, environmental, and
endogenous factors [18, 19].
Early evidence of the genetic component of
ATD was supported by several familial and twins studies.
Early twins studies estimated the concordance rate for
disease in identical (monozygotic twins to be 50-70%,
and 3-25% for non-identical (dizygotic) twins for
autoimmune hypothyroidism [20].  Later studies reported
concordance rate of 35% in monozygotic twins. As the
concordance rates for the disease fall below 100% in
monozygotic twins, that share the identical DNA,
environmental (nongenetic) factors must play a role in
the development of autoimmune thyroiditis. In one study,
the λs (ratio of the prevalence in siblings of affected
individuals to the prevalence in the general population)
was 16.9 (>5 being significant), indicating an important
role of genetic susceptibility [21].
This genetic susceptibility shows necessity of
familial regular screening.
Advances in genetic methods in the past 15
years enabled significant progress in the identification of
complex disease genes. A number of review articles in
recent years have been published describing the genetic
background of the autoimmune thyroid disease.
Candidate gene analysis, whole-genome linkage
screening, genome-wide association studies, and whole-
genome sequencing are the major technologies that
have advanced this field, leading to the identification of
at least seven genes whose variants have been
associated with AITD [22].
Some of these susceptibility genes are specific
to either Graves disease (GD) or Hashimoto thyroiditis,
while others showed susceptibility to both diseases. 
The identified ATDs susceptibility genes can be
divided into two broad groups: (1) immune modulating
genes, and (2) thyroid specific genes.
The first group immunomodulatory genes
include: HLA-DR, CD40, cytotoxic T lymphocyte-
associated factor (CTLA-4), and protein tyrosine
phosphatase 22 (PTPN22), while the second group
includes the thyroglobulin (Tg) and TSH receptor genes.
The first identified ATD susceptibility gene locus
was the human leukocyte antigen DR (HLA-DR) gene
locus. Several studies showed association of Hashimoto
thyroiditis with HLA-DR3 and HLA-DR4 antigens [23-
25].
Recently, Zeitlin et al. investigated DRB1-DQB1-
DQA1 haplotypes in the largest UK Caucasian Hashimoto
thyroiditis case control cohort to date comprising 640
Hashimoto thyroiditis patients and 621 controls. A strong
association between HT and DR4 haplotype (DRB1*04-
DQB1*03-QA1*03) was detected, and protective effects
were detected for DR13 haplotype (DRB1*13-DQB1*06-
DQA1*01) and DR7 [27].
CD40 is expressed primarily on B-cells and
other antigen presenting cells (APC), and plays a
fundamental role in B-cell activation and antibody
secretion and generation of memory cells. Since CD40
is a major APC and B-cell costimulatory molecule, it
seems plausible that CD40 will play a role in the genetic
susceptibility to other autoimmune diseases. Tomer et
al.  have demonstrated that the CC genotype at the 5’
untranslated region of CD40 is linked and associated
with Graves’ disease [27].
Table 1: Epidemiological characteristics of children and
adolescents with HT reported in recent published studies.
339
Zdraveska & Kocova M. Hashimoto Thyroiditis in Childhood
Maced J Med Sci. 2012 Oct 15; 5(3):336-345.
Indeed, recent data have shown that CD40 was
associated and/or linked with high IgE levels in asthma
[28], rheumatoid arthritis [29], systemic lupus
erythematosus [30], and multiple sclerosis [31].
CTLA-4 is a transmembrane protein of the
immunoglobulin (Ig) superfamily, an important molecule
that acts as a major negative regulator of T-cell activation
by binding to the B7 molecules present on antigen-
presenting cells and preventing the second signal
necessary for T-cell activation. CTLA-4 gene
polymorphism is established as an autoimmunity gene
shown to be linked and/or associated with various
autoimmune conditions. These include both GD and HT,
as well as the production of thyroid antibodies alone
without clinical disease [32].
Protein tyrosine phosphatase22 (PTPN22)
encodes a protein, lymphoid tyrosine phosphatase (LYP),
which is a potent inhibitor of the T-cell receptor signaling
pathway. A tryptophan for arginine substitution at codon
620 of the LYP molecule has been associated with both
Graves’ disease and Hashimoto thyroiditis in some but
not all ethnic populations [33-35].
In a recent study performed in Japanese
population, a novel protective effect of a haplotype
containing five SNPs in this gene was observed for HT
[36].
Antibodies against thyroid peroxidase are one
of the most specific features of HT. Therefore, the thyroid
peroxidase gene was expected to be a putative candidate
responsible for susceptibility to HT. However, case-
control studies showed lack of association between the
thyroid peroxidase gene polymorphisms and ATD. These
data suggest that the thyroid peroxidase gene does not
play an important role in predisposition to HT [37, 38].
The thyroglobulin (Tg) is the major thyroid
autoantigen in autoimmune thyroid disease, evidenced
by the fact that HT is characterized by antithyroglobulin
antibodies detected in almost all of the patients. Both
linkage and association studies further localized these
polymorphisms to two new Tg microsatellites in introns
10 and 27.Detailed sequence analysis of the Tg gene
demonstrated significant associations between specific
Tg single nucleotide polymorphisms (SPNs) and both
Graves’ disease and HT in three different data sets [36,
39].
Within the other thyroid-specific gene, the TSHR
gene was mapped on chromosome 14q. A number of
different SNPs of the TSH receptor have been associated
with autoimmune thyroid disease [40].
One of the many unexpected findings of these
genetic studies was that most of the identified genes
have very minor effects; most of them with a low odd
ratios of <1.5 [41].
It is usually supposed that a strong genetic
effect on disease is related to the inheritance of many
genes with small effect. Two alternative mechanisms
have been proposed for the very low odd ratios
involvement for most ATDs genes: subset effect and
gene-gene interactions.
According to the “gene-gene interaction” model,
two genes with weak effects interact, biologically resulting
in a combined odd ratio that is significantly higher than
the one expected with an additive effect alone.
According to the “subset” or genetic
heterogeneity model each of the genetic variants
identified has a large effect resulting in a high odd ratio
in a subset of the ATD patients studied. However, when
these variants are tested in the entire population of ATD
patients, their effects are diluted, resulting in much
smaller odd ratios [42].
Genetic factors predominate, accounting for
approximately 80% of the likelihood of developing
ATDs,whereas at least 20% is due to non-genetic factors.
Several environmental and non-genetic triggers have
been implicated in the etiology of HT including nutrition,
stress, infection, trauma, medications and irradiation.
Iodine is one of the most important precipitants of thyroid
dysfunction. Although essential for normal thyroid
function, excess iodine supplementation can be
associated with the onset of thyroid autoimmunity. Several
studies have demonstrated increased incidence of
autoimmune thyroiditis in regions where iodine
consumption is high compared to regions with low
consumption [5, 433, 44].
Selenium (Se) may play an essential role in
thyroid hormone synthesis: two enzymes involved in the
thyroid hormone pathway are selenoproteins, namely
deiodinases and glutathione peroxidase. Adequate Se
nutrition supports efficient thyroid hormone synthesis
and metabolism and protects the thyroid gland from
damage from excessive iodine exposure.
Derumeaux et al. discovered an inverse
association between Se status and thyroid volume and
echostructure in French adults and concluded that Se




beneficial effects when treating patients with autoimmune
thyroiditis with selenomethionine for 6 months due to its
ability to reduce anti-TPO antibodies [46].
The most common medications that may play a
role in the development of HT are: amiodarone, interferon-
α, interleukin-2, lithium, and antiretroviral therapy.
Several infections have been implicated in the
pathogenesis of HT including Helicobacter pylori, Borrelia
burgdorferi, Yersinia enterocolitica, Coxsackie virus,
and retroviruses. The strongest association of
Hashimoto’s thyroiditis with an infectious agent is with
Hepatitis C virus [47].
Irradiation of the thyroid gland, as in therapy for
malignancies, may predispose to autoimmunity due to
exposure of thyroidal antigens to the immune system.
Many environmental pollutants, such as polyaromatic
hydrocarbons, perfluorinated chemicals, phthalates, and
bisphenol A, have been shown to be toxic to thyroid cells
and promote the onset of HT [48]. These chemicals are
widely used in various industrial and consumer products.
Pathogenesis
In an initial stage of the pathogenesis, antigen-
presenting cells (APC), mostly dendritic cell and
macrophage infiltrate the thyroid gland. The infiltration
can be induced by some envinromental triggering factor
which causes insult on thyrocytes and release of thyroid-
specific proteins.
These proteins serve as a source of self-antigenic
peptides that are presented on the cell surface of APC
after processing. A central phase of HT is characterized
by the recognition of presented autoantigens by the
lymphocytes, followed by an apparent uncontrolled
production of autoreactive CD4+ T cells, CD8+ cytotoxic
T cells and autoantibodies. In a final, destructive stage
of Hashimoto’s thyroiditis, the autoreactive T cells in
large numbers  infiltrate thyroid parenchyma, causing
massive depletion of thyrocytes via antibody-dependent,
cytokine mediated and apoptotic mechanisms.
Thyroglobulin (Tg) is one of the major
autoantigens in thyroid autoimmunity and serologic
studies have shown that there are at least 40 antigenic
epitopes on human Tg. Tg-antibodies are detected in
almost all patients with ATD. Anti-thyroglobulin antibodies
were also reported in up to 27% of normal individuals
[49, 50].
Thyroid peroxidase (TPO) is another significant
autoantigen in the thyroid in patients with HT. This
enzyme catalyses the oxidation of iodine to an iodinating
species that forms iodotyrosines in a Tg molecule and
subsequently iodotyronines. TPO antibodies are
heterogeneous and so far, around 180 human TPO
antibodies have been cloned and sequenced [51].
Autoantibodies against other thyroid-specific
antigens such as thyrotropin receptor and sodium iodide
symporter were also found in serum of HT patients.
However, these antibodies occur rarely and do not
contribute to the diagnosis of HT. Histologically, goitrous
HT is characterized by a diffuse lymphocytic infiltration
with occasional germinal centers. Thyroid follicles may
be reduced in size and contain sparse colloid. Individual
thyroid cells are often enlarged, with oxyphilic cytoplasm
(usually defined Hurthle cells). In contrast, the gland of
atrophic AT is small, with lymphocytic infiltration and
fibrous replacement of the parenchyma [52].
Hence, with a loss of functional thyroid tissue
caused by these processes, hormonal depletion leads to
hypothyroidism.
Clinical manifestations
The most common clinical manifestations of
Hashimoto thyroiditis are goiter and hypothyroidism.
Clinical manifestations at the time of presentation can
vary from euthyroidism to different degrees of thyroid
dysfunction, either overt or subclinical forms of
hypothyroidism and very rarely hyperthyroidism.
Asymptomatic enlargement of the thyroid gland
is a common presenting complaint, especially in older
children and adolescents. The goiter may appear
insidiously and may be small or large. In most patients,
the thyroid is diffusely enlarged, firm, and nontender. In
about 30% of patients, the gland is lobular and may
seem to be nodular [53].
Occasionally, complaint of “sore” neck in
extended position might be reported by the patient. As
the disease progresses, subclinical and then clinical
hypothyroidism appears. The clinical manifestations due
to hypothyroidism will depend on the age of onset in
childhood. Young children (1-3 years) can present with
coarse facial features, hoarse cry and deceleration of
linear growth, while onset later in childhood can be
accompanied by features such as lethargy, constipation,
growth retardation, muscular pseudohypertrophy,
delayed or, rarely, precocious sexual development. Older
children and adolescents may present with any of the
following features: deterioration in academic
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performance, delayed skeletal maturation, delayed
puberty and myxedematous appearance.
De Vries  et al in their study investigated the
clinical manifestations of autoimmune thyroiditis in 114
children, at the mean age 11.8 years. The most common
reason for referral was goitre, in 39% of patients; and the
actual prevalence on examination was almost twofold
higher (77%). In almost one-third of patients, ATD was
diagnosed in the absence of clinical symptoms, either
incidentally or on routine screening for high-risk groups
[11]. The patients considered to be at high risk showed
no significant differences in anthropometric, clinical or
laboratory data compared to the patients referred for
goitre. Also the same was the prevalence of overt
hypothyroidism in this group as in patients referred for
goitre or clinical symptoms of hypothyroidism, concluding
that periodic thyroid function tests may be indicated in
people at high risk of ATD.
It should be remembered that the underlying
autoimmunity may predispose involvement of multiple
organs and endocrine glands.
Hashimoto thyroiditis may be the initial
presentation of an autoimmune polyglandular syndrome.
It also can be associated with other coexisting
autoimmune diseases such as diabetes mellitus type 1,
celiac disease, Addison’s disease, pernicious anemia.
Kordonouri et al. in a multicenter survey
investigated the thyroid autoimmunity in a very large
nationwide cohort of 17,749 patients with type 1 diabetes
aged 0.1–20 years that were treated in 118 pediatric
diabetes centers in Germany and Austria. Significantly
elevated titers of at least one thyroid antibody were
found in 1,530 patients (21.6%) supporting previous
findings from smaller cohorts of a high prevalence of
thyroid autoimmunity in children and adolescents with
type 1 diabetes [54]. In other study in Caucasian
populations with diabetes in the U.S., thyroid
autoimmunity prevalence of even 50% has been reported
[55].
All these data support the recommendation for
regular, i.e., yearly, examinations of thyroid antibodies,
in all children with type 1 diabetes starting from onset of
diabetes or, at latest before puberty. In cases of positive
antibodies, thyroid function tests and ultrasound
assessment are recommended in order to minimize the
risk of undiagnosed hypothyroidism in young patients.
Celiac disease (CD) has increasingly become
considered as a multi-organ disorder and has been
linked to a number of diseases including autoimmune
disorders. Several studies have shown a positive
association of celiac disease with increased prevalence
of autoimmune thyroid antibodies. In prospective studies
of adults with CD, autoimmune thyroid disease was
observed in 14% and 30.3% of patients. Ansaldi et al
provided a multicenter study that included 343 biopsy
proven CD patients, aged 9 months to 18 years.
Autoimmune thyroid disease was found in 90 (26.2%) of
the CD patients, even those on a gluten free diet.  This
high prevalence points the importance of thyroid status
assessment at diagnosis and at follow up evaluation in
children with CD [56]. Meloni at al. in their study reported
10.5% prevalence of autoimmune thyroiditis in 324
children with proven celiac disease in Sardinia, Italy [57].
The coexistence of papillary thyroid carcinoma
and HT is  reported to range from 10% to 58% in various
studies [58]. The prevalence of HT in patients with
papillary thyroid carcinoma has been reported to be
significantly higher compared to the prevalence of benign
thyroid tumours. Patients with HT are suggested to be at
higher risk for papillary thyroid carcinoma compared
with patients without HT [59].
Hashimoto’s encephalopathy (HE) is an under-
recognized cause of acute encephalopathy both in
children and adults.  It is always associated with elevated
levels of antithyroid antibodies and sometimes associated
with chronic lymphocytic thyroiditis and goiter [60].
Adequate information is not available about the frequency
of Hashimoto’s encephalopathy in children. The
prevalence in adult patients is estimated to be 2.1/
100,000 [61].
The clinical picture of a relapsing and remitting
encephalopathy characterized by seizures, stroke-like
episodes, neurological signs such as myoclonus and
tremor, cognitive disturbance and hallucinations, and
other psychotic symptoms is highly suggestive of
Hashimoto’s encephalopathy [62].
Normal routine investigations, nonspecific
neuroimaging and CSF findings (apart from elevated
protein), and encephalopathic EEG can be supportive of
the diagnosis. Thyroid hormone studies are not helpful,
but may identify subclinical thyroid dysfunction [62].
Detection of antithyroid (in particular anti-TPO) antibodies
confirms the diagnosis. As anti-TPO antibodies are
detected in as many as 10 % of the general population,
high titers (usually over 100-fold normal) [63] of these
antibodies in conjunction with the clinical features of




diagnosis can be made. Corticosteroid responsiveness
can also support the diagnosis.
Diagnosis
Thyroid function is estimated by measuring FT4
and TSH. Euthyroid AT is diagnosed if both FT4 and TSH
are normal. The typical patient with hypothyroidism
secondary to AT will have an elevated TSH (“typically”
over 10 IU/mL), a low FT4, and positive titer of anti-TPO
antibodies. Subclinical hypothyroidism is defined as
TSH elevation with normal concentrations of circulating
thyroid hormones (FT4 and FT3).
Majority of these patients are asymptomatic, but
many studies suggest that individuals with the combined
risk factors of TSH level above the normal limit and
positive thyroid antibodies (anti-TG or anti-TPO) are at
high risk for progression to overt hypothyroidism.
Therefore, thyroid hormone replacement treatment is
recommended in all patients with TSHvalues >10 IU/mL
or with TSH values >5 IU/mL in combination with goiter
and thyroid autoantibodies [64]. Anti-TPO antibodies
are the most sensitive screening for AT. Little further
benefit is gained by the additional measurement of anti-
TG antibodies, although they may be added if anti-TPO
titers are negative [64].
Hashimoto’s thyroiditis is diagnosed based on
findings of seropositivity for Tg autoantibodies and/or
TPO autoantibodies, accompanied by at least one of the
following: abnormal thyroid function; enlarged thyroid
gland; morphological changes on thyroid ultrasound;
cytomorphological features of chronic lymphocytic
thyroiditis on fine needle aspiration. Fine needle aspiration
that was more frequently performed in the past is not
necessary for the diagnosis, although it might be helpful
in cases with nodules, or unusual finding on ultrasound.
Ultrasonography (USG) is a proved useful tool
in the evaluation of thyroid diseases. Reduced
echogenicity on USG is considered to be characteristic
of AT. The degree of hypoechogenicity was not only
found to have a significant correlation with the levels of
circulating thyroid antibodies and thyroid dysfunction,
but was also shown to predict the evolution towards
hypothyroidism in euthyroid subjects [65, 66].
Therapy
Children with hypothyroidism should be treated
with levothyroxine replacement therapy. Thyroid hormone
replacement has been used for more than 100 years in
the treatment of hypothyroidism, and there is no doubt
about its overall efficacy.  A starting dose can be estimated
based upon the patient’s age and body weigh.
Levothyroxine has good intestinal absorption and its
long halflife of 5–7 days allow oral administration once a
day. Levothyroxine should be administered at least 20
min, before eating or ingestion of any medication known
to impair its absorption, such as calcium and iron
supplements, sucralfate, potassium-binding resins,
antacids containing aluminium, and bile-acids binding
resins. All other medications should be checked for
interactions, particularly with antidepressants and seizure
medications.
Although very rare, the development of
pseudotumor cerebri associated with the initiation of
levothyroxine has been described in a small number of
school-age children [67].
Also long-standing untreated hypothyroidism
might cause hyperplasia of the pituitary thyrotrophs
mimicking pituitary macroadenoma. Kocova et al.
reported 11-year old girl with long-standing acquired
primary hypothyroidism leading to pituitary pseudotumor
that improved rapidly after the introduction of therapy
with L-thyroxine. Review of the few other described
cases in the literature led to conclusion that the possibility
of pituitary hyperplasia due to primary hypothyroidism
should be taken into consideration whenever an enlarged
homogeneous pituitary gland in children is detected
[68].
There is considerable debate regarding the
management of children with euthyroidism or subclinical
hypothyroidism. At the same time, studies have shown
that treating subclinical hypothyroidism may confer
benefits, such as delay of progression to overt
hypothyroidism [69], reduction of the thyroid size [70],
improvement of the lipid profile [71], and correction of
growth velocity [72].
Svensson et al. in their study investigated the
effect of levothyroxine treatment on thyroid size in 90
children with autoimmune thyroiditis. Their results showed
that levothyroxine treatment is effective in reducing
thyroid volume in pediatric patients and is suggested in
treatment of goiter caused by autoimmune thyroiditis
especially in cases of hypothyroid, but also in euthyroid
children [7]. Consensus statement on subclinical thyroid
dysfunction has recommended LT4 therapy for adults
with subclinical hypothyroidism, in whom serum TSH
levels are greater than 10 mIU/L [73]. Since no such
consensus exists regarding children with subclinical
hypothyroidism, clinical judgment is advised taking into
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consideration the need for constant monitoring of therapy
and ensuring compliance with therapy.
The natural history of HT in children and
adolescents is not fully known. Few studies have
examined the spontaneous evolution of the disease [9].
A recent Italian retrospective study described the outcome
of 160 children affected with HT followed for up to 32.6
years in 20 paediatric endocrine clinics [74].  At 5 years
of follow-up, more than 50% of the patients remained or
became euthyroid.The authors analyzed reliable
prognostic factors to predict disease evolution. However,
there were no differences regarding clinical measures,
thyroid volume, and antibody concentrations in the group
with normal TSH levels and the group with elevated TSH
levels.
Parents of children with AT should be advised
that the hypothyroidism is likely to be permanent and
monitoring of thyroid function for all patients should be
lifelong. The prognosis for recovering lost linear growth
depends on the duration of the hypothyroidism as well as
the age when the treatment was initiated.
Some authors offer a trial off L-T4 therapy to
adolescents, after the completion of growth and puberty.
Thyroid function is retested 6–8 weeks after the
discontinuation of medication, to determine if
hypothyroidism is permanent and potentially restart
therapy [64].
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